Growth differentiation factor 15 agonist - Eli Lilly and Company
Alternative Names: GDF15 agonist - Eli LillyLatest Information Update: 28 Aug 2022
At a glance
- Originator Eli Lilly and Company
- Class Antihyperglycaemics
- Mechanism of Action Growth differentiation factor 15 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA
- 29 Jul 2019 Phase-I clinical trials in Diabetes mellitus in USA (Eli Lilly pipeline, July 2019)